Frédéric Jean Mercier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frédéric Jean Mercier has a total of 521 co-authors. Here are the top co-authors by number of shared publications:
D. Benhamou
22 shared publicationsDan Benhamou
Anaesthesia and critical care department, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France
15 shared publications- Agnès Le Gouez
Departement d' Anesthesie, Hôpital Antoine Beclère, France
10 shared publications D Benhamou
9 shared publicationsMarie-Pierre Bonnet
Anaesthesia and critical care department, Cochin teaching hospital, groupement hospitalier universitaire Ouest, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75679 Paris cedex 14, France; Paris 05 René-Descartes University, 75006 Paris, France; Inserm, UMR S953, epidemiological research unit on perinatal health and women's and children's health, maternité Port Royal, Cochin teaching hospital, 75014 Paris, France; UMR S953, UPMC Paris 06 university, 75005 Paris, France
9 shared publications- D. Benhamou
CHU, Le Kremlin-Bicêtre, FRANCE
7 shared publications
Latest Publications
- 27 November 2024
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 38 (3) , 187-198
Cesarean delivery: Clinical updates
- 27 November 2024
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 38 (3) , 187-198
Cesarean delivery: Clinical updates
- Open Access
- 23 May 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (4) , 101394
Obstetric units' preparedness to manage critically ill women. The second report from the MaCriCare study
- 23 May 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (4) , 101394
Open AccessObstetric units' preparedness to manage critically ill women. The second report from the MaCriCare study
- Open Access
- 1 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2656
Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage
Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio: 0.11; 95% confidence interval: 0.03–0.35). In OS-1, more rFVIIa-exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio: 2.46; 95% confidence interval: 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa-exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- 1 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2656
Open AccessEfficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage
Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio: 0.11; 95% confidence interval: 0.03–0.35). In OS-1, more rFVIIa-exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio: 2.46; 95% confidence interval: 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa-exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- Open Access
- 4 March 2024
- Published by MDPI AG in Preprints.org
Efficacy and Safety Analysis of Recombinant Factor VIIa in Severe Post-partum Hemorrhage
Background: Despite a range of available treatments, there is a remaining unmet need for patients with severe post-partum hemorrhage (sPPH). Objective: This manuscript evaluated efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 [NCT04723979], OS-2, OS-3 and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligation, arterial embolization or hysterectomy) and safety (incidence of thromboembolic events [TE] and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa exposed women only. Results: A total of 446 women exposed to rFVIIa and 1,717 non-exposed controls were included. In the RCT, fewer rFVIIa exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio 0.11, 95% confidence interval 0.03–0.35). In OS-1, more rFVIIa exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio 2.46, 95% confidence interval 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio 0.33, 95% confidence interval 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa in the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- 4 March 2024
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Safety Analysis of Recombinant Factor VIIa in Severe Post-partum Hemorrhage
Background: Despite a range of available treatments, there is a remaining unmet need for patients with severe post-partum hemorrhage (sPPH). Objective: This manuscript evaluated efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 [NCT04723979], OS-2, OS-3 and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligation, arterial embolization or hysterectomy) and safety (incidence of thromboembolic events [TE] and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa exposed women only. Results: A total of 446 women exposed to rFVIIa and 1,717 non-exposed controls were included. In the RCT, fewer rFVIIa exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio 0.11, 95% confidence interval 0.03–0.35). In OS-1, more rFVIIa exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio 2.46, 95% confidence interval 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio 0.33, 95% confidence interval 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa in the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- Open Access
- 13 February 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (3) , 101355
Preparedness for severe maternal morbidity in European hospitals: The MaCriCare study
- 13 February 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (3) , 101355
Open AccessPreparedness for severe maternal morbidity in European hospitals: The MaCriCare study
- 4 October 2023
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 131 (6) , e183-e185
Reversible cerebral vasoconstriction syndrome after neostigmine and atropine administration for postdural puncture headache
- 4 October 2023
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 131 (6) , e183-e185
Reversible cerebral vasoconstriction syndrome after neostigmine and atropine administration for postdural puncture headache
- Open Access
- 13 October 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 129 (6) , 937-945
Tranexamic acid dose–response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study
- 13 October 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 129 (6) , 937-945
Open AccessTranexamic acid dose–response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study
- 8 October 2022
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 52, 103601
Seizures due to neurocysticercosis in a postpartum French Congolese woman: sometimes it is the zebra
- 8 October 2022
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 52, 103601
Seizures due to neurocysticercosis in a postpartum French Congolese woman: sometimes it is the zebra